Patents by Inventor Saad Shaaban

Saad Shaaban has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multi-target drug candidates for the treatment of triple-negative breast cancer
    Patent number: 11970464
    Abstract: Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary
  • 2-ethoxy-8-(4-fluorobenzylidene)-4-(4-fluorophenyl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile as an antimicrobial compound
    Patent number: 11970453
    Abstract: An 2-ethoxy-8-(4-fluorobenzylidene)-4-(4-fluorophenyl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 28, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mohamed Gouda, Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Saad Shaaban, Antar Ahmed Abdelhamid Ahmed
  • 7-(4-fluorobenzylidene)-4-(4-fluorophenyl)-2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile as an antimicrobial compound
    Patent number: 11970455
    Abstract: A 7-(4-fluorobenzylidene)-4-(4-fluorophenyl)-2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: December 8, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mohamed Gouda Mahmoud, Hany Mohamed Abd El-Latef Ahmed, Mai Mostafa Khalaf Ali, Saad Shaaban, Antar Ahmed Abdelhamid Ahmed
  • Multi-target drug candidates for the treatment of triple-negative breast cancer
    Patent number: 11964947
    Abstract: Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: April 23, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary
  • Multifunctional diorganyl diselenide tethered cellulose as a corrosion inhibitor of stainless steel
    Patent number: 11920060
    Abstract: New diorganyl diselenide compounds are described herein, as well as the use of such diorganyl diselenide compounds in forming anticorrosion coatings for stainless steel. Also described are methods for forming the new diorganyl diselenide compounds as well as anti-corrosion coatings containing the diorganyl diselenide compounds.
    Type: Grant
    Filed: August 21, 2023
    Date of Patent: March 5, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saad Shaaban, Amr Negm, Hany Mohamed Abd El-Lateef Ahmed, Tarek Ahmed Yousef, Ahmed S. M. Aljanabi
  • Multi-target drug candidates for the treatment of triple-negative breast cancer
    Patent number: 11891363
    Abstract: Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: February 6, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary
  • Antiproliferative selenated-folate hybrids
    Patent number: 11845750
    Abstract: Novel organoselenium compounds formed with folates that can be used to maximize anticancer activity of the organoselenium. Novel organoselenium compounds that can be used as a chemopreventive against cancer. These compounds may be present in pharmaceutical compositions and may be used in various treatment methods.
    Type: Grant
    Filed: August 7, 2023
    Date of Patent: December 19, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Amr Negm, Saad Shaaban, Yasair S. Al-Faiz